Archived: 3rd Winter Conference
on Medicinal & Bioorganic Chemistry
January 24th - 29th 1999
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 24th 1999
Optimization in Chemical Synthesis
Program Chair: Victor Snieckus, Queen’s University
Introduction
Metal-Catalysed Asymmetric Oxidations
From Cincholoipin and Cantharidin to the Present
Monday, January 25th 1999
Optimization in Chemical Synthesis (cont.)
Program Chair: Victor Snieckus, Queen’s University
Recent Advances in the Process R&D of Novel AIDS Therapeutics
Catalysis as a Key Technology for Environmentally Benign Synthesis of Pharmaceutically Important Amines and Amino
The Chemistry-Medicine Continuum: the Design of New Reactions in Connection with the Design of New Therapeutic Agents
The Total Synthesis of Cryptophycins, Potent Marine Natural Product Oncolytics
Domino Reactions in Organic Synthesis, A Contribution to Efficiency, Economy, and Ecology in Chemistry
Methodologies for Parallel Array Medicinal Chemistry
Program Chair: Dan Flynn / Gunda Georg
Strategies for Parallel Synthesis: an Overview
Parallel Synthesis with Fluorous Phase Reagents and Reactants
Soluble Polymers in Parallel Array Synthesis
Tuesday, January 26th 1999
Methodologies for Parallel Array Medicinal Chemistry (cont.)
Program Chair: Dan Flynn / Gunda Georg
Building Blocks on Resins
Sequestration Methods for Purification in Array Synthesis. Application to Specific Drug Discovery Projects
Experimental Design Tools for Parallel Array Synthesis: Can We Shorten the Time from Synthesis Design to Validated Chemistry?
Applications of Structural Biology to Drug Discovery
Program Chair: Christie G. Broulliette, University of Alabama-Birmingham
Predicting Binding Energetics from Structure: Looking Beyond ∆G
Structure and Energetics of Phosphotyrosine Protein-Peptide Complexes
Analysis of the Binding Surfaces of Proteins
Applications of Mass Spectrometry for Target Identification and Characterization
SH2 domains: from Structure to Energetics, a Dual Approach to the Study of Structure/Function Relationships
Wednesday, January 27th 1999
KEYNOTE | “Academic Organic Synthesis…Where do we go from here?”
Program Chair: Prof. Stephen Hannesian, Universite de Montreal
General Paper | WCMBC Student/Postdoctoral Fellowship Presentations
Program Chair: Peter Andrews, University of Queensland
Impurity Annihilation: A Strategy for Solution Phase Combinatorial Chemistry with Minimal Purification
An Iterative Synthesis of Semicorrins, Tripyrrolines and Related Materials
Constitutive Activation o’ G-Protein Coupled Receptors
The Quest for Novel Antibiotics: Alkene Metathesis in the Construction of B-Lactams
Trfluoromethylacivicin as a Mechnaistic Probe for IGP Synthase
Inhibition of Breast Cancer Cell and Tumor Growth by Derivatives of AZT and AZU
Synthesis Applications of Aymmetric Horner-Wadsworth-Emmons Condensations: Approaches to Marine Natural Products
Novel Benzothiepine Ileal Bile Acid Transporter (IBAT) Inhibitors for the Treatment of Hypercholesterolemia
General Oral Papers | Poster Session
Program Chair: Michael Rafferty
New Applications of High Specific Activity [36S]Sulfonamides for Photoalfinity Labelling
Oral Delivery of Low Molecular Weight Heparin in Rats and Primates
3-[3-Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT 1D Agonists
Automated Solid Phase Organic Synthesis: Synthesis of Organic Molecules Through the Use of Air-Sensitive Reagents
Synthesis and Biochemical Evaluation of Phthalimido Derivatives as Potential Inhibitors of the D-Glutamic Acid-Adding Enzyme
Ligands for the Tyrosine Kinase p56kk SH2 Domain: Discovery of Potent Dipetides with Monocharged, Non-hydrolyzable Phoshate Replacements
Design and Synthesis of a x-Conotoxin MVIIa Peptidomimetic
The Synthesis of Cleavable Mass Spectrometry Tags: A System for SNP Genotyping
Thursday, January 28th 1999
Impact of Genomics Technologies on Pharmaceutical Research
Program Chair: Gary McMaster, Parke-Davis Pharmaceutical Research
Introduction
Genetics, Genomics and Drug Discovery
Mouse Genetics/Genomics: Approaches for Identification of New Therapeutic Targets
Overview of the Human Genome Project
High Throughput Screening of Gene Expression: It’s Emerging Role in Drug Discovery
Genetically tagged-Proteins for Functional Proteomics and Beyond
Using Model Animals to Identify Targets and Leads for Human Therapeutics
Multi-Drug Resistance
Program Chair: Lester Mitscher, University of Kansas
Nature and Dimensions of the Problem
Recent Progress in Novel Macrolides, Quinolones and Pyridones Directed at Overcoming Resistance
Antitumor Compounds from Tunicates
Friday, January 29th 1999
Multi-Drug Resistance (cont.)
Program Chair: Les Mitscher, University of Kansas
Antimicrobial Resistance v.s. Small Molecules (i.e. The Chemical Evolution)
Novel Erythromycin Analogs by Genetic Engineering
Multiple Drug Resistance Inhibitors as Adjuncts in Anticancer Chemotherapy
Microbal Resistance: Novel Screens for a Contemporary Problem
Combinatorial Chemistry Aided Anti-bacterial Drug Discovery
Novel Antitumor Agents from Higher Plants